Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 11/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | MLLT3 | P42568 | 3/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | YEATS2 | Q9ULM3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24011032 | 0.85 | MLLT1 (0.56) | MLLT1MAOBMLLT3NLRP3KDM4E | |
| SCHEMBL22123559 | 0.77 | MLLT1 (0.49) | MLLT1MAOBNAMPTMLLT3NLRP3 | |
| SCHEMBL22124957 | 0.77 | MLLT1 (0.45) | MLLT1MAOBKDM4EPOLBMAPT | |
| SCHEMBL23432690 | 0.76 | MLLT1 (0.49) | MLLT1MAOBDNMT1NAMPTMLLT3 | |
| SCHEMBL22566647 | 0.75 | MLLT1 (0.47) | MLLT1MAOBMLLT3NLRP3YEATS2 | |
| SCHEMBL38660996 | 0.74 | MAOB (0.46) | MLLT1MAOBMLLT3NLRP3POLB | |
| SCHEMBL22750927 | 0.73 | MLLT1 (0.76) | MLLT1MAOBKDM4EMAPT | |
| SCHEMBL25309225 | 0.71 | MAOB (0.46) | MLLT1MAOBPOLBMAPT | |
| SCHEMBL24783499 | 0.70 | MLLT1 (0.45) | MLLT1MAOBDNMT1MLLT3NLRP3 | |
| SCHEMBL25124502 | 0.70 | MLLT1 (0.46) | MLLT1MAOBDNMT1MLLT3NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898633-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020127504-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | MLLT1 1606/4885MAOB 2706/4885DNMT1 2474/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | MLLT1 1606/4885MAOB 2706/4885DNMT1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.